As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.
List view / Grid view
19 March 2018 | By Anis H. Khimani (PerkinElmer)
Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.
19 March 2018 | By Drug Target Review
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
28 February 2018 | By Molecular Devices
Cellular imaging acquisition and analysis system at an affordable price point.
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
Reasons for phenotypic vs. target based drug discovery strategies, challenges of and maximising return of phenotypic assays.
23 January 2018 | By PerkinElmer
Water immersion lenses provide: brighter images from HCS samples; faster and gentler imaging; higher quality images from both 2D and 3D samples.
12 January 2018 | By Dr Zara Kassam (Drug Target Review)
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals the patches significantly improved recovery from heart attack injury...
In this application note, PerkinElmer demonstrates the ease and utility of the AlphaScreen® cAMP assay for detecting both agonist and antagonist-induced cAMP responses within cells.
Application note: LANCE Ultra TR-FRET – based detection and modulation of Phosphorylated STAT3 levels in human cells
In this application note, PerkinElmer demonstrates how LANCE® Ultra, a homogeneous assay format, can be used to quickly and accurately assess modulation of pSTAT3.
Scientific poster: Developing protein: Protein Interaction (PPI) assays with AlphaLISA and LANCE TR-FRET
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.
13 December 2017 | By Dr. Paul Wylie (Head of Applications at TTP Labtech)
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
12 December 2017 | By Drug Target Review
DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.
12 December 2017 | By Joesph Zock (Product Managemenr at IntelliCyt)
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.